The telemedicine sector is red hot right now. Indeed, the innovation this sector provides has been necessary as a result of the pandemic.
However, for those banking on the long term, this sector could be a great one to invest in right now. Pandemic-friendly stocks are selling off right now. For those who believe in a telemedicine-oriented future, now’s the time to buy.
High demand driving growth
The pandemic resulted in a surge in patient demand for telemedicine solutions. Many doctors’ offices simply wouldn’t let patients come in for various reasons. Being able to treat non-acute medical issues via a virtual modality is something that has become second nature to many healthcare providers and patients of late.
It wasn’t always this way. The healthcare sector is one that hasn’t changed much over the past century. It’s a sector that’s traditionally been difficult to innovate in. Companies like Dialogue Health are re-shaping this argument.
Surging demand and regulatory requirements combined to provide the perfect tailwind for Dialogue to go public. Since going public, this stock has waned, trading nearly 40% below its all-time high. This comes despite rather bullish numbers released by the company of late.
Dialogue’s virtual platform features a lucid user interface and a well-organized architecture. These have been instrumental in expanding this company’s large customer base. This is a 24/7 multi service hub with more than 2,000 direct customers and 50,000 customers via its various partnerships. Dialogue links individuals with over 500 multifaceted healthcare providers across a number of clinical specialties in primary and mental health care.
5 Stocks Under $49 (FREE REPORT)Click here to gain access!
Analysts are bullish on Dialogue
After Dialogue became listed on the TSX on March 30, David Newman, an analyst at Desjardins Securities, initiated coverage of the company. He’s bullish on this stock owing to different factors, which he pointed out in his recent research report.
These include Dialogue’s excellent position in the virtual care space, and the company’s focus on the B2B market, which is currently poised for disruption. This company has an ideal business model, which has ensured a high customer-retention rate. Moreover, Dialogue has displayed strong revenue generation consistently.
Furthermore, Dialogue’s advanced platform is one that’s highly scalable. With an efficient management team steering the ship, many expect this company to produce some impressive growth long-term. This growth could potentially be supplemented by additional M&A activity over the medium term.
Undoubtedly, there appears to be a tonne of upside for Dialogue, as it continues to implement its effective strategy to build its one-of-a-kind Integrated Health Platform. It certainly has the potential to grow its operations and extend its offering to new locations via strategic acquisitions.
I believe that Dialogue is well positioned to disrupt a sector that many believed as impossible to penetrate. Accordingly, this company represents the innovation of the future.
Indeed, that’s something every long-term investor can get behind.
Like this top pick? Here are a few more to consider right now:
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Chris MacDonald has no position in any of the stocks mentioned.